Replimune Group (REPL) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Replimune Group (REPL) has outperformed Taysha Gene Therapies (TSHA) over the past year, gaining 183.9% versus a loss of 6.1%. Over five years, REPL leads with a -56.2% price change compared with -75.2% for TSHA. Taysha Gene Therapies is the larger company by market cap ($1.44 billion vs $1.24 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | REPL | TSHA |
|---|---|---|
| Share price | $13.20 | $4.43 |
| Market cap | $1.24B | $1.44B |
| 1-day change | -0.38% | +0.91% |
| YTD return | +35.80% | -19.45% |
| 1-year return | +183.87% | -6.14% |
| 5-year return | -56.22% | -75.22% |
| EPS (TTM) | $-3.15 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.33 | $7.30 |
| 52-week low | $1.50 | $3.69 |
| Distance from 52-week high | -19.17% | -39.32% |
| Average volume | 4.20M | 3.24M |
| Shares outstanding | 94.22M | 325.83M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed TSHA by 190.0 percentage points over the past year.
REPL vs TSHA FAQ
Which is bigger, Replimune Group or Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) is larger, with a market capitalization of $1.44B compared with $1.24B for Replimune Group (REPL).
Which stock has performed better over the past year, REPL or TSHA?
REPL returned +183.87% over the past 12 months, compared with -6.14% for TSHA (price return, excluding dividends). Past performance does not predict future results.
Are Replimune Group and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.